The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis.

Papadokostakis G, Damilakis J, Mantzouranis E, Katonis P, Hadjipavlou A

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society29 Sept 2005Cited by 22 (Europe PMC)

PMID16193299PMCIDPMC3489300DOI10.1007/s00586-005-0916-4PepBankPUB-16193299

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporotic postmenopausal women with chronic back pain, salmon calcitonin produced no significant pain intensity effects across the studied groups.
In plain wordsIn postmenopausal women with osteoporosis and back pain, pain effects did not differ significantly between salmon calcitonin with calcium and calcium alone.
Peptide
Calcitonin-salmon
Outcome
No significant changePain intensity
Study
n = 110
Comparator
Calcium alone
Outcome group
Pain · Musculoskeletal
Studied dose
200 IU daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
Repeated measures ANOVA showed that there were no significant time, group or interaction effects for pain intensity and disability in any of the groups studied.
2 context sentences(design, population, supporting numbers)
Summary · context
The study design involved three groups of osteoporotic postmenopausal women suffering from chronic back pain.
Summary · context
The patients were randomly assigned to receive, for three months, either 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA) or 1,000 mg of oral calcium daily (groups IB, IIB, IIIB).
Report a problemFND-1619329901
02HumanRandomized controlled trialEfficacy outcome
In osteoporotic postmenopausal women with chronic back pain, salmon calcitonin produced no significant disability effects across the studied groups.
In plain wordsIn postmenopausal women with osteoporosis and back pain, disability effects did not differ significantly between salmon calcitonin with calcium and calcium alone.
Peptide
Calcitonin-salmon
Outcome
No significant changeDisability
Study
n = 110
Comparator
Calcium alone
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
200 IU daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
Repeated measures ANOVA showed that there were no significant time, group or interaction effects for pain intensity and disability in any of the groups studied.
2 context sentences(design, population, supporting numbers)
Summary · context
The study design involved three groups of osteoporotic postmenopausal women suffering from chronic back pain.
Summary · context
The patients were randomly assigned to receive, for three months, either 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA) or 1,000 mg of oral calcium daily (groups IB, IIB, IIIB).
Report a problemFND-1619329902
03HumanNon-randomized trialEfficacy outcome
In osteoporotic women with vertebral fractures, Oswestry scores decreased nonsignificantly during salmon calcitonin treatment.
In plain wordsIn women with osteoporosis and vertebral fractures, disability scores decreased during salmon calcitonin treatment, without a significant change from baseline.
Peptide
Calcitonin-salmon
Outcome
No significant changeOswestry score in vertebral fractures
Study
n: not reported in source
Comparator
Baseline
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
200 IU daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
Mean Oswestry and NRS scores were reduced during the follow-up period in the groups IA, IIIA, but the differences between the two time points were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Group I consisted of 40 women with vertebral fractures, group II of 30 women with degenerative disorders and group III of 40 patients with non specific chronic back pain and without abnormality on plain X-rays.
Summary · context
The study design involved three groups of osteoporotic postmenopausal women suffering from chronic back pain.
Summary · context
The patients were randomly assigned to receive, for three months, either 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA) or 1,000 mg of oral calcium daily (groups IB, IIB, IIIB).
Report a problemFND-1619329903
04HumanNon-randomized trialEfficacy outcome
In osteoporotic women with vertebral fractures, NRS pain scores decreased nonsignificantly during salmon calcitonin treatment.
In plain wordsIn women with osteoporosis and vertebral fractures, pain scores decreased during salmon calcitonin treatment, without a significant change from baseline.
Peptide
Calcitonin-salmon
Outcome
No significant changeNRS in vertebral fractures
Study
n: not reported in source
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Studied dose
200 IU daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
Mean Oswestry and NRS scores were reduced during the follow-up period in the groups IA, IIIA, but the differences between the two time points were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Group I consisted of 40 women with vertebral fractures, group II of 30 women with degenerative disorders and group III of 40 patients with non specific chronic back pain and without abnormality on plain X-rays.
Summary · context
The study design involved three groups of osteoporotic postmenopausal women suffering from chronic back pain.
Summary · context
The patients were randomly assigned to receive, for three months, either 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA) or 1,000 mg of oral calcium daily (groups IB, IIB, IIIB).
Report a problemFND-1619329904
05HumanNon-randomized trialEfficacy outcome
In osteoporotic women with nonspecific back pain, Oswestry scores decreased nonsignificantly during salmon calcitonin treatment.
In plain wordsIn women with osteoporosis and nonspecific back pain, disability scores decreased during salmon calcitonin treatment, without a significant change from baseline.
Peptide
Calcitonin-salmon
Outcome
No significant changeOswestry score in nonspecific back pain
Study
n: not reported in source
Comparator
Baseline
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
200 IU daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
Mean Oswestry and NRS scores were reduced during the follow-up period in the groups IA, IIIA, but the differences between the two time points were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Group I consisted of 40 women with vertebral fractures, group II of 30 women with degenerative disorders and group III of 40 patients with non specific chronic back pain and without abnormality on plain X-rays.
Summary · context
The study design involved three groups of osteoporotic postmenopausal women suffering from chronic back pain.
Summary · context
The patients were randomly assigned to receive, for three months, either 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA) or 1,000 mg of oral calcium daily (groups IB, IIB, IIIB).
Report a problemFND-1619329905
06HumanNon-randomized trialEfficacy outcome
In osteoporotic women with nonspecific back pain, NRS pain scores decreased nonsignificantly during salmon calcitonin treatment.
In plain wordsIn women with osteoporosis and nonspecific back pain, pain scores decreased during salmon calcitonin treatment, without a significant change from baseline.
Peptide
Calcitonin-salmon
Outcome
No significant changeNRS in nonspecific back pain
Study
n: not reported in source
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Studied dose
200 IU daily · intranasal · three monthsAs given in this study (human).
Source sentences
Summary
Mean Oswestry and NRS scores were reduced during the follow-up period in the groups IA, IIIA, but the differences between the two time points were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Group I consisted of 40 women with vertebral fractures, group II of 30 women with degenerative disorders and group III of 40 patients with non specific chronic back pain and without abnormality on plain X-rays.
Summary · context
The study design involved three groups of osteoporotic postmenopausal women suffering from chronic back pain.
Summary · context
The patients were randomly assigned to receive, for three months, either 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA) or 1,000 mg of oral calcium daily (groups IB, IIB, IIIB).
Report a problemFND-1619329906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.